Generics

  • FDA approves Sun's generic Strattera

    MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.

    Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.

    Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.

  • Sigmapharm files ANDA for generic Hepsera

    FOSTER CITY, Calif. A generic drug maker has filed an abbreviated new drug application for its version of a Gilead Sciences drug.

    FOSTER CITY, Calif. A generic drug maker has filed an abbreviated new drug application for its version of a Gilead Sciences drug.

  • IMS Health exec to NACDS conference attendees: Expect opportunities, uncertainties for drug market

    SAN DIEGO The U.S. drug market will present opportunities as well as uncertainties over the next decade, according to remarks made by IMS Health VP industry relations Doug Long at the National Association of Chain Drug Stores’ 2010 Pharmacy and Technology Conference held here on Monday.

     

  • Salix settles MoviPrep patent dispute with Novel

    RALEIGH, N.C. Salix Pharmaceuticals announced its agreement with Novel Labs to settle its patent litigation over Novel’s proposed generic version of MoviPrep.

     

  • FDA approves Amneal generic for treatment of hypertension and liver cirrhosis

    HAUPPAUGE, N.Y. The Food and Drug Administration has approved a generic treatment for hypertension and liver cirrhosis made by Amneal Pharmaceuticals, Amneal said Thursday.

     

    The FDA approved Amneal’s spironolactone hydrochloride tablets in the 25 mg, 50 mg and 100 mg strengths. The drug is a generic version of Pfizer’s Aldactone. Various versions of the drug had sales of $91 million in 2009, according to IMS Health.

     

     

  • Teva launches generic version of popular antidepressant

    NORTH WALES, Pa. Teva Pharmaceutical Industries has launched a generic version of a weekly formulation of a popular antidepressant, the generic drug maker said.

     

    Teva announced the launch of fluoxetine delayed-release capsules, a generic version of Eli Lilly’s Prozac Weekly.

     

    NORTH WALES, Pa. Teva Pharmaceutical Industries has launched a generic version of a weekly formulation of a popular antidepressant, the generic drug maker said.

     

  • Teva introduces generic drug that lowers blood pressure

    NORTH WALES, Pa. Teva Pharmaceutical Industries has introduced a generic drug for lowering patients’ blood pressure, the world’s largest manufacturer of generic drugs said Monday.

    Teva introduced clonidine transdermal system, a generic version of Boehringer Ingelheim’s Catapres-TTS. The drug is available in 0.1 mg, 0.2 mg and 0.3 mg strengths and comes in the form of a patch designed for daily application.

    The drug has annual sales of around $297 million, according to IMS Health.

  • Mylan markets generic Solodyn ER

    PITTSBURGH Mylan has launched a generic treatment for acne, the company said Thursday.

    Mylan announced the launch of minocycline hydrochloride extended-release tablets in the 45 mg, 90 mg and 135-mg strengths. The drug is a generic version of Solodyn ER, made by Medicis Pharmaceuticals Corp.

     

    Minocycline ER had sales of around $496 million during the 12-month period ended in March, according to IMS Health.

     

  • Sandoz first to receive FDA approval for Lovenox generic

    SILVER SPRING, Md. The Food and Drug Administration has approved the first generic version of a Sanofi-Aventis injected drug used to treat deep vein thrombosis, the agency said Friday.

     

    The FDA approved generic enoxaparin sodium, a version of Sanofi’s Lovenox, developed under a collaboration between Momenta Pharmaceuticals and Sandoz, the generics division of Swiss drug maker Novartis.

     

     

  • GPhA: Generic drug utilization can curb wasteful Medicaid spending

    WASHINGTON A reported excess of a quarter billion dollars is a good case for increasing use of generic drugs under the Medicaid program, according to the main lobby for the generic drug industry.

     

    Responding to a report by conservative think tank the American Enterprise Institute that identified $271 million in wasteful Medicaid spending, the Generic Pharmaceutical Association said it was a “compelling case” for increasing generic drug utilization.

     

     

X
This ad will auto-close in 10 seconds